KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash & Equivalents (2016 - 2025)

West Pharmaceutical Services' Cash & Equivalents history spans 16 years, with the latest figure at $484.6 million for Q4 2024.

  • For Q4 2024, Cash & Equivalents fell 43.25% year-over-year to $484.6 million; the TTM value through Dec 2024 reached $484.6 million, down 43.25%, while the annual FY2024 figure was $484.6 million, 43.25% down from the prior year.
  • Cash & Equivalents for Q4 2024 was $484.6 million at West Pharmaceutical Services, up from $446.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $898.6 million in Q3 2023 and bottomed at $335.3 million in Q1 2020.
  • The 5-year median for Cash & Equivalents is $601.8 million (2024), against an average of $633.1 million.
  • The largest annual shift saw Cash & Equivalents surged 40.17% in 2020 before it crashed 43.97% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $615.5 million in 2020, then grew by 23.9% to $762.6 million in 2021, then grew by 17.27% to $894.3 million in 2022, then dropped by 4.52% to $853.9 million in 2023, then tumbled by 43.25% to $484.6 million in 2024.
  • Per Business Quant, the three most recent readings for WST's Cash & Equivalents are $484.6 million (Q4 2024), $446.2 million (Q2 2024), and $601.8 million (Q1 2024).